{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:42:55Z","timestamp":1780569775628,"version":"3.54.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["213684\/NCT04551989"],"award-info":[{"award-number":["213684\/NCT04551989"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Evaluate the long-term safety and effectiveness of mepolizumab in subgroups of patients with eosinophilic granulomatosis with polyangiitis, including: disease duration, oral corticosteroid (OCS) use, relapse, worsening or new-onset symptoms, anti-neutrophil cytoplasm antibodies (ANCA) status, and immunosuppressive therapy use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the 96-week MARS study in Japan were analysed for patients receiving mepolizumab for \u226596\u00a0weeks, focusing on adverse events (AEs), clinical symptoms, average daily OCS dose, and relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>OCS exposure decreased in most subgroups, particularly in the ANCA negative subgroup. Patients on higher average OCS doses (&amp;gt;7.5\u00a0mg\/day vs \u22647.5\u00a0mg\/day, during the observation period) experienced more AEs, including infection-related AEs and clinical symptoms, and higher relapse rates. No relapses were observed in patients on an average dose of 0.0\u00a0mg\/day OCSs. Reduced OCS use was associated with improved clinical outcomes, particularly in patients who remained relapse-free.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mepolizumab was effective regardless of eosinophilic granulomatosis with polyangiitis duration, ANCA status, or immunosuppressant use. Higher OCS doses were linked to more AEs, clinical symptoms, and relapses compared to lower doses. In relapse-free patients, continued mepolizumab use led to fewer AEs, lower OCS doses, and improved symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf096","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T11:51:35Z","timestamp":1760442695000},"page":"272-281","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A subgroup analysis of the MARS study"],"prefix":"10.1093","volume":"36","author":[{"given":"Tomonori","family":"Ishii","sequence":"first","affiliation":[{"name":"Clinical Research Innovation and Education Center, Tohoku University Hospital , Sendai ,","place":["Japan"]},{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kunishige","sequence":"additional","affiliation":[{"name":"Global Real World Evidence and Health Outcomes Research, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Biostatistics, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Respiratory, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Komatsubara","sequence":"additional","affiliation":[{"name":"Global Real World Evidence and Health Outcomes Research, GSK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alfonso-Cristancho","sequence":"additional","affiliation":[{"name":"Global Real World Evidence and Health Outcomes Research, GSK , Collegeville, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2026030508170989900_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103219","article-title":"Eosinophilic granulomatosis with polyangiitis: a review","volume":"22","author":"White","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026030508170989900_ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.627776","article-title":"Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology","volume":"8","author":"Fagni","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026030508170989900_ref3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jaip.2020.07.038","article-title":"Antineutrophil cytoplasmic antibodies and organ-specific manifestations in eosinophilic granulomatosis with polyangiitis: a systematic review and meta-analysis","volume":"9","author":"Chang","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026030508170989900_ref4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.mayocp.2023.02.013","article-title":"HES and EGPA: two sides of the same coin","volume":"98","author":"Khoury","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"2026030508170989900_ref5","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1007\/s10067-021-05783-8","article-title":"Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis","volume":"40","author":"Jakes","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026030508170989900_ref6","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/mr\/road104","article-title":"Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: real-world database analysis","volume":"34","author":"Sada","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026030508170989900_ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1145257","article-title":"Eosinophilic granulomatosis with polyangiitis\u2013advances in pathogenesis, diagnosis, and treatment","volume":"10","author":"Fijolek","year":"2023","journal-title":"Front Med"},{"key":"2026030508170989900_ref8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/mr\/roab007","article-title":"The prevalence, burden of disease, and healthcare utilization of patients with eosinophilic granulomatosis with polyangiitis in Japan: a retrospective, descriptive cohort claims database study","volume":"32","author":"Sada","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026030508170989900_ref9","doi-asserted-by":"publisher","first-page":"AB54","DOI":"10.1016\/j.jaci.2023.11.191","article-title":"Patient perspectives on the burden of eosinophilic granulomatosis with polyangiitis","volume":"153","author":"Merkel","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2026030508170989900_ref10","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.3390\/jcm9123890","article-title":"Role of cytokines in EGPA and the possibility of treatment with an anti-IL-5 antibody","volume":"9","author":"Isozaki","year":"2020","journal-title":"J Clin Med"},{"key":"2026030508170989900_ref11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) consensus task force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"key":"2026030508170989900_ref12","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0170-2022","article-title":"Eosinophilic granulomatosis with polyangiitis: case report and literature review","volume":"18","author":"Alam","year":"2022","journal-title":"Breathe"},{"key":"2026030508170989900_ref13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.18553\/jmcp.2016.22.7.833","article-title":"Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma","volume":"22","author":"Dalal","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2026030508170989900_ref14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acr2.11263","article-title":"Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America","volume":"3","author":"Doubelt","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"2026030508170989900_ref15","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","article-title":"Anti\u2013IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels","volume":"121","author":"Stein","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2026030508170989900_ref16","volume-title":"Highlights of Prescribing Information","author":"GSK"},{"key":"2026030508170989900_ref17","volume-title":"Nucala, Mepolizumab","author":"Eurpean Medicines Agency"},{"key":"2026030508170989900_ref18","volume-title":"Nucala, Mepolizumab","author":"GSK"},{"key":"2026030508170989900_ref19","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2026030508170989900_ref20","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/mr\/roae100","article-title":"Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: long-term observation of the MARS study","volume":"35","author":"Ishii","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026030508170989900_ref21","volume-title":"Introductory Guide MedDRA Version 26.0","author":"MedDRA"},{"key":"2026030508170989900_ref22","first-page":"403","article-title":"Post\u2013marketing surveillance of mepolizumab use in patients with eosinophilic granulomatosis with polyangiitis in Japan: interim analysis","volume":"42","author":"Fujii","year":"2021","journal-title":"J Ther Res"},{"key":"2026030508170989900_ref23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2500\/aap.2015.36.3863","article-title":"Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use","volume":"36","author":"Zazzali","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"2026030508170989900_ref24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2026030508170989900_ref25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.alit.2020.08.005","article-title":"The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients","volume":"70","author":"Kitamura","year":"2021","journal-title":"Allergol Int"},{"key":"2026030508170989900_ref26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/24725625.2021.1916159","article-title":"Successful early introduction of mepolizumab for peripheral neuropathy with a peripheral circulatory disorder in a patient with myeloperoxidase anti-neutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Nishihara","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"2026030508170989900_ref27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026030508170989900_ref28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13223-023-00801-7","article-title":"Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Masumoto","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2026030508170989900_ref29","doi-asserted-by":"publisher","first-page":"1183156","DOI":"10.3389\/fphar.2023.1183156","article-title":"Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma","volume":"14","author":"Domingo","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026030508170989900_ref30","doi-asserted-by":"publisher","first-page":"103398","DOI":"10.1016\/j.jaut.2025.103398","article-title":"Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): a European real-life retrospective comparative study","volume":"153","author":"Mattioli","year":"2025","journal-title":"J Autoimmun"},{"key":"2026030508170989900_ref31","doi-asserted-by":"publisher","first-page":"1204444","DOI":"10.3389\/fimmu.2023.1204444","article-title":"Effectiveness and safety of anti-IL-5\/R\u03b1 biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study","volume":"14","author":"Nolasco","year":"2023","journal-title":"Front Immunol"},{"key":"2026030508170989900_ref32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13075-023-03097-5","article-title":"Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan","volume":"25","author":"Yamane","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2026030508170989900_ref33","doi-asserted-by":"publisher","first-page":"AB375","DOI":"10.1016\/j.jaci.2023.11.899","article-title":"A real-world study of mepolizumab in patients with EGPA and HES: insights in rare eosinophilic disease","volume":"153","author":"Pongdee","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2026030508170989900_ref34","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/annrheumdis-2023-eular.5282","article-title":"AB0776 real-world evidence on the long-term use and drug survival of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA)","volume":"82","author":"Koutsianas","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026030508170989900_ref35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.anai.2024.11.004","article-title":"Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States","volume":"134","author":"Mathur","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026030508170989900_ref36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13223-023-00863-7","article-title":"Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study","volume":"20","author":"Chapman","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2026030508170989900_ref37","doi-asserted-by":"publisher","first-page":"17534666241308406","DOI":"10.1177\/17534666241308406","article-title":"A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT)","volume":"19","author":"Cheng","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"2026030508170989900_ref38","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1007\/s12325-024-02967-x","article-title":"Real-world effectiveness of mepolizumab in severe asthma: results from the multi-country, self-controlled Nucala effectiveness study (NEST)","volume":"41","author":"Al-Lehebi","year":"2024","journal-title":"Adv Ther"},{"key":"2026030508170989900_ref39","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026030508170989900_ref40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.alit.2024.12.005","article-title":"Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: improvements in rhinosinusitis imaging (J-Real-Mepo)","volume":"74","author":"Nagase","year":"2025","journal-title":"Allergol Int"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf096\/64710647\/roaf096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/2\/272\/64710647\/roaf096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/2\/272\/64710647\/roaf096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:17:17Z","timestamp":1772716637000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/2\/272\/8286791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf096","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,10,15]]}}}